[{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"TRK-950","moa":"CAPRIN1","graph1":"Oncology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"TRK-950","moa":"CAPRIN1","graph1":"Oncology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TRK-950","moa":"CAPRIN1","graph1":"Oncology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TRK-950","moa":"CAPRIN1","graph1":"Oncology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Bolt Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||CAPRIN1","graph1":"Oncology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Toray Industries \/ Toray Industries","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Toray Industries"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Toray Industries","highestDevelopmentStatusID":"10","companyTruncated":"Toray Industries \/ Toray Industries"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"TRK-170","moa":"Integrin alpha-4\/beta-1 (ITGA4\/B1)","graph1":"Immunology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nalfurafine","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Immunis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Immunis"},{"orgOrder":0,"company":"Toray Industries","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Toray Industries \/ Toray Industries","highestDevelopmentStatusID":"10","companyTruncated":"Toray Industries \/ Toray Industries"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Toray Industries","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Toray Industries"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TRK-100STP","moa":"Prostacyclin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Toray Industries","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Toray Industries"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TRK-100STP","moa":"Prostacyclin receptor","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Astellas Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Toray Industries \/ Astellas Pharma"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"prostaglandins","graph1":"Nephrology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Astellas Pharma"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Nephrology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TRK-250","moa":"TGF-beta-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TRK-700","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TRK-700","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TRK-750","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TRK-750","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Toray Industries
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
